Tag: PulseRider
FDA approves PulseRider device for marketing
The FDA has approved PulseRider (Cerenovus) device to be marketed. The device is indicated for use with neurovascular embolic coils in patients 18 years...
Cerenovus introduced at SNIS
Johnson & Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the Society of NeuroInterventional Surgery 14th Annual Meeting (SNIS; 24–28 July,...
Codman Neuro announces acquisition of Pulsar Vascular Inc
Codman Neuro has announced the acquisition of Pulsar Vascular Inc, a privately-held company with breakthrough platform technology for the neurovascular treatment of complex aneurysms. DePuy...
ANSWER study for wide-neck aneurysms meets primary endpoints
In the ANSWER (Adjunctive neurovascular support of wide-neck aneurysm embolization and reconstruction) study of the PulseRider device (Pulsar Vascular), enrolment, 30-day and 180-day follow-up...
First coil key during PulseRider procedures in wide-neck aneurysms
At the 2015 annual meeting of the European Society of Minimally Invasive Neurological Therapy (ESMINT; 10–12 September, Nice, France) Gyula Gal (Department of Radiology,...
Enrolment complete for PulseRider US clinical trial
Pulsar Vascular has announced that they have reached the target enrolment in their clinical trial for PulseRider device for the treatment of intracranial aneurysms....
PulseRider safe and effective in early USA experience
Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid terminus.
Codman Neuro gains exclusive rights to market and promote PulseRider in...
PulseRider is a minimally invasive device intended for use with embolic coils in the treatment of unruptured wide-neck intracranial aneurysms originating on or near a bifurcation.
FDA IDE approval for PulseRider
The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near a bifurcation of the basilar tip or carotid terminus.
Pulsar Vascular gets CE mark for Pulserider
Pulsar Vascular announced that it has received European CE mark approval for Pulserider. This unique implant is used to bridge the neck of cerebral aneurysms previously not amenable to endovascular therapy. This new device is implanted via standard, minimally invasive, endovascular techniques thus providing an alternative treatment option to open surgery.
